When the denial is clinical, the appeal should be physician-authored.
Clinovian helps U.S. providers and RCM partners turn high-value clinical denials into evidence-mapped physician arguments. Start with a no-PHI AR audit; if recovery potential is clear, Clinovian prepares appeals, P2P briefs, DRG arguments, or NSA/IDR clinical dossiers.
Clinical consulting only. Clinovian is not a law firm and does not provide U.S. legal advice or legal representation. Legal strategy, filing decisions, and jurisdiction-specific advice remain with the client's counsel or designated legal representative.
No-PHI Clinical Denial AR Audit
The sale is intentionally low-risk: Clinovian first identifies whether your denied AR contains recoverable clinical value before requesting records or formalising a larger engagement.
Aged clinical denial AR
Prioritise high-value medical-necessity, DRG, and specialty denials by contestability, deadline risk, and estimated recovery.
Physician escalation layer
Add clinical argument capacity without hiring internal physicians. White-label or co-branded support available.
High-value specialty denials
Support for radiology, anesthesia, emergency medicine, surgery, oncology, infusion, and other clinically complex disputes.
P2P and concurrent review
Prepare treating physicians for payer calls with concise criteria-mapped briefs and exact clinical counterarguments.
Clinical Denial AR Audit
A focused 72-hour triage of your aged denial inventory that shows what is worth pursuing, what is deadline-critical, and what should be abandoned.
What the audit answers
Which denial categories appear clinically contestable?
Which cases should move first based on value and filing window?
Which path fits each bucket: appeal, P2P, IDR dossier, external review, or abandon?
Why this works commercially: the buyer is not asked to replace a vendor or move PHI upfront. They only test whether abandoned revenue is recoverable.
What exactly should you send first?
Send this for the first audit
The first review is designed to work from de-identified, operational denial data.
- Payer name and plan type
- Denial category and denial rationale
- Denial date and appeal deadline if known
- Claim value / outstanding AR amount
- Service line and current appeal level
- De-identified denial letters or sample rationales
- CSV or Excel aged AR extract with identifiers removed
Do not send this initially
PHI moves only after scope, agreement, BAA, and secure transfer workflow are in place.
- Patient names, MRNs, DOBs, addresses, or full claim forms
- Full charts, operative notes, lab reports, or imaging reports
- Screenshots containing patient identifiers
- Unredacted denial letters
- Medical records through ordinary email
- Any PHI into public or non-BAA AI tools
CSV template available on request. Recommended columns: payer, plan type, denial type, claim value, denial date, appeal deadline, service line, denial rationale, current appeal level, and de-identified notes.
Clinovian is selective by design.
Best-fit matters
- High-value medical-necessity denials
- DRG downgrades or paid-at-wrong-level disputes
- Scheduled P2P calls needing criteria-mapped briefing
- Specialty clinical denials with complex record evidence
- NSA/IDR cases requiring clinical complexity explanation
- RCM partners needing a physician-authored escalation layer
Not a fit
- Low-value administrative denials
- Routine registration, eligibility, or COB errors
- Bulk claims processing or call-center workflows
- Patients seeking individual medical advice
- Providers needing U.S. legal representation
- Claims where all appeal pathways have closed with no viable alternate route
Ordinary appeals describe the case. Clinovian maps the case to the payer's decision logic.
Generic appeal
“The patient was clinically unstable and required inpatient care.”
Problem: true, but not enough. It does not identify the criterion, threshold, timestamp, intervention, or payer pathway being disputed.
Criteria-mapped appeal
“MCG inpatient severity criterion satisfied by lactate elevation, persistent hypotension, AKI markers, IV resuscitation, and serial monitoring documented across the first hospital day.”
Advantage: the reviewer can see the exact denial logic being answered with record-based evidence, not general clinical disagreement.
Inspect the work before you engage.
Physician appeal letter
Criterion-by-criterion inpatient medical-necessity appeal with record evidence, threshold logic, and escalation-ready structure.
Denial AR assessment
Specimen 72-hour no-PHI audit showing recoverable AR, deadline risk, payer pattern analysis, and recommended case sequence.
Arbitrator-facing dossier
Federal No Surprises Act IDR dossier with QPA rebuttal, statutory factor mapping, and clinical complexity narrative.
| Engagement | Best for | Commercial structure | Buyer risk |
|---|---|---|---|
| No-PHI AR Audit | Hospitals and groups with aged clinical denial inventory | Fixed fee or complimentary for qualified portfolios | Low — no PHI required initially |
| Single denial appeal | High-value medical necessity, DRG, or specialty denial | Per-case fee based on complexity and claim value | Medium — focused single-case test |
| P2P brief | Scheduled payer medical-director call | Urgent flat fee, 24–48 hour workflow | Low — specific call deliverable |
| NSA / IDR dossier | Out-of-network dispute requiring clinical complexity argument | Per dispute or batch arrangement | Medium — deadline-driven filing support |
| RCM partner support | RCM companies needing physician-authored escalation | White-label monthly or per-case arrangement | Low — you retain client relationship |
| Physician advisory | Ongoing UM / case-management support | Monthly retainer | Predictable recurring support |
Exact pricing depends on case complexity, claim value, payer type, deadline proximity, and volume. The AR Audit is designed to determine whether a larger engagement is economically justified.
Do not send PHI until the workflow is formalised.
Clinovian operates from India with U.S.-provider-facing contractual safeguards. The first AR Audit does not require PHI. Clinical records are accessed only after written scope, BAA, and secure transfer workflow.
Positioning shift: Clinovian is not bulk offshore claims processing. It is a physician-authored clinical argument practice for high-value disputes where the record needs to be translated into payer-review logic.
Send denied AR first. No PHI required.
Receive a 72-hour physician-level recovery assessment before committing records, budget, or operational time.
Every appeal is constructed around an understanding of how a payer reviewer actually processes a case.
The underlying principle: an appeal that does not address the specific criterion applied by the reviewer is not an appeal — it is a clinical narrative. The distinction determines the outcome.
Clinovian's review approach draws directly from utilisation management physician reviewer experience inside a major U.S. commercial payer. That operational background — daily application of MCG and InterQual criteria, direct engagement with the review workflow, and familiarity with the documentation patterns that distinguish approved cases from sustained denials — informs how every case is handled: which criterion paths are recognised immediately, which data points are extracted from the medical record, and how each submission is structured for the physician reviewer who will evaluate it.
Identify the exact criteria path or review logic driving the denial.
Extract the medical record evidence that answers that logic directly.
Deliver a physician-authored argument structured for the next escalation level.
Six failure modes that explain why most clinical denials are lost before they begin.
No criteria mapping
The appeal explains why care was appropriate but never addresses the specific criterion cited in the denial letter. The reviewer reads it as "no new information."
Wrong criteria set assumed
The appeal argues against MCG when the payer used InterQual, or references general medical criteria when procedure-specific logic applied.
Clinical narrative without evidence extraction
The physician writes a letter explaining the patient's condition. The data that satisfies the specific threshold — the lab value, the timestamp, the vasopressor dose — is never explicitly cited.
Outdated criteria version referenced
MCG and InterQual update annually. The appeal cites a criterion that has changed. The payer reviewer recognizes the mismatch immediately.
No escalation architecture
The appeal is written as a one-shot letter. When it fails at Level 1, there is no differentiated argument for Level 2, no preparation for external review, and no ERISA procedural lever.
Deadline expiration
The appeal window — 60 to 180 days for most commercial payers, 60 days for Medicare Advantage — expires before a physician-level argument is ever assembled.
What these have in common: none are caused by the clinical record being wrong. They are caused by the appeal being poorly constructed. The evidence exists — it was never assembled in the language the reviewer evaluates.
What happens in real review
Requests arrive in a queue. The reviewer pulls the criteria path, scans for explicit evidence, and moves quickly. If the submitted record does not clearly satisfy the applied criterion, denial is often the path of least resistance.
Consequence: implicit clinical logic does not win. Evidence must be mapped to the exact review standard.
Why hospitals lose after discharge
Retrospective denials and RAC/MAC challenges occur after the stay, often months later. The clinical record may support the original decision, but the argument was never assembled in the language the payer audit process demands.
Operational reality: retrospective denials are not closed cases. They are usually under-argued cases.
Severity logic and inpatient threshold
MCG criteria hinge on objective severity markers — specific vital sign thresholds, lab value ranges, clinical findings. Satisfaction requires the specific number, timestamp, and clinical context — not a clinical narrative. Cases are lost when the record contains the right evidence but the appeal does not explicitly map to the applied threshold.
Subset logic and intervention specificity
InterQual uses a subset system — primary diagnosis → applicable subset → level-of-care criteria. More intervention-specific than MCG, requiring documentation of specific interventions (e.g., "IV vasopressor infusion initiated"), not just the clinical state. Absence of specific intervention language results in denial even when the intervention was clearly performed.
The most common appeal failure: the provider submits a letter explaining why care was appropriate. The reviewer sustains denial because the letter never directly addresses the criteria cited in the original denial. The misapplication patterns — wrong criteria set, outdated version, wrong level-of-care logic — also create independent appeal arguments that most providers never raise.
ERISA vs. state law: two different appeal paths, two different leverage points.
ERISA-governed plans
Most employer-sponsored plans are governed by ERISA. ERISA preempts state insurance law, creating a federal framework with specific procedural requirements that the payer must follow — and that create independent appeal arguments when violated.
- Plan document consistency — was the denial consistent with the plan's stated criteria?
- Administrative record — was the review process compliant with ERISA procedures?
- Procedural deadline arguments — did the payer respond within required timeframes?
- Disclosure requests — the provider may request the full administrative record under ERISA
State-regulated plans
Non-ERISA plans — individual market, Medicaid managed care, state employee plans — fall under state insurance regulation. Many states provide stronger external review protections, step-therapy reform laws, and Independent Medical Review (IMR) rights.
- State IMR — independent physician review not employed by the payer. California IMR overturns ~60% of oncology denials.
- Step-therapy reform — CA, NY, TX and others require exception when clinical contraindication is documented
- State external review standards — often more favorable procedural grounds than ERISA
How Clinovian integrates this: Regulatory and procedural arguments are built directly into the clinical appeal document where they strengthen the case. This is clinical consulting that recognizes the full appeal environment; legal strategy remains with client counsel.
The complete escalation path — and where Clinovian operates at each level.
| Level | Description | Typical Timeline | Clinovian Role |
|---|---|---|---|
| P2P | Direct physician-to-physician call before or during formal appeal | 24–72 hrs from notice | Criteria-mapped briefing document with counterarguments |
| L1 Internal | First formal appeal to payer UM | 60–180 days (commercial); 60 days (MA) | Physician-authored criteria-mapped appeal |
| L2 Internal | Second internal appeal to different reviewer or committee | Plan-dependent | Escalated argument building on L1 with additional evidence |
| External / IRO | Independent Review Organisation — not a payer employee | 60 days post-final internal decision | Full IRO-standard submission |
| State IMR | State-mandated Independent Medical Review | State-specific | Specialist-reviewer-standard document |
| ERISA Federal | For employer-sponsored plans — federal framework | Varies | Regulatory + clinical combined brief |
| ALJ (RAC/MAC) | Administrative Law Judge — Medicare appeals Level 3 | After Redetermination + QIC | Complete administrative record construction |
Critical deadlines: Commercial internal: 60–180 days from denial date. Medicare Advantage: 60 days. Urgent concurrent review: 72 hours. External review: 60 days post-final internal. RAC ADR response: 45 days. These are non-renewable — once elapsed, the appeal right is permanently forfeited.
Secure intake
Denial letter, records, and supporting material received only through a BAA-governed secure workflow after scope approval.
Criteria identification
The exact review path is identified — MCG, InterQual, payer-specific — before any document is written.
Record extraction
Labs, vitals, notes, MAR, imaging, and documentation relevant to the dispute are isolated with timestamps.
Argument construction
Physician-authored, criteria-mapped document built for the next payer decision point with escalation architecture.
Delivery & escalation
Case-ready material delivered with recommended next-step escalation logic through the full appeal hierarchy.
Six service lines, each designed for a different point in the denial cycle.
Tier A services are immediate-response engagements. Tier B services are revenue-recovery engagements for high-value clinical disputes.
Pricing is quoted after the denial type, claim value, deadline pressure, and PHI-review requirements are understood. This section explains how clients usually start, so buyers know what kind of commercial structure to expect before contacting Clinovian.
No-PHI AR Audit
A small paid review of de-identified AR to decide whether larger appeal work is worth it. For qualified portfolios, this fee can be applied toward later appeal work if the client proceeds.
P2P Brief
Used when a payer medical-director call is already scheduled. Typical 24–48 hour workflow when documents are available.
Complex Denial Appeal
For medical necessity, DRG, or specialty denials. Quote depends on claim value, appeal level, chart size, and deadline risk.
IDR Dossier
For deadline-driven NSA/IDR submissions. Batch pricing may apply when multiple similar disputes are being prepared together.
RCM Layer
For RCM companies needing recurring physician escalation capacity. Can be white-label, co-branded, or referral-based.
Under the No Surprises Act, providers can initiate Independent Dispute Resolution for OON emergency and facility-based claims. The arbitrator selects one of two offers — the provider’s or the insurer’s — based on submitted evidence. Clinovian prepares a physician-authored clinical dossier that organizes clinical complexity, statutory-factor evidence, and QPA-rebuttal support for counsel/client review.
Factor 03 — acuity and complexity — is the most decisive additional circumstance for clinical disputes. This factor requires a physician to construct a genuine clinical argument about risk stratification, comorbidity burden, intervention complexity, and clinical decision-making. Many non-clinical submissions struggle to explain this factor with sufficient medical specificity. Clinovian supplies the physician-authored clinical argument layer.
- Independent EM groups with OON exposure at in-network facilities
- Radiology and anaesthesiology groups at in-network hospitals
- Surgical and procedural specialists with NSA-covered OON claims
- RCM companies needing physician clinical argumentation layer for IDR portfolios
Per-case engagement. Per-case scope available. The determination timeline is more measurable than many ordinary denial projects. The feedback loop is clearer than long-cycle provider appeals. IDR is the fastest path to demonstrating Clinovian’s clinical argumentation quality before committing to a longer-term denial appeal engagement.
Public IDR data has recently shown strong provider-side outcomes, but results vary by service, geography, payer, and dossier quality. No outcome is guaranteed.
Treating physicians know the patient, not the payer's criteria path. Most P2P calls are lost because the physician walks in with a clinical story instead of a criteria-specific rebuttal.
- Applied criteria path and likely denial logic
- Mapped evidence from chart to criterion
- Payer counterarguments and prepared responses
- Fallback argument lines
- 4–8 page structured physician briefing document
Any scheduled P2P call with a payer medical director. No minimum claim threshold. Highest-probability single intervention in the denial cycle.
Hospital case management teams, treating physicians, revenue cycle leaders facing a scheduled P2P call.
Community hospitals (100–400 beds) cannot justify $250K–$400K/year for a full-time physician advisor but are required under CMS CoP to have one.
- Concurrent review support
- Observation vs. inpatient guidance
- P2P call coverage for active cases
- Documentation guidance aligned to payer review logic
- Discharge planning advisory and UM committee support
Guidance on what specific documentation language the payer reviewer will evaluate — prevention before the denial is issued, not response after.
Community hospitals (100–400 beds) needing fractional physician advisor capacity. Hospitals with acute denial rate increases.
Organizations know they have aged clinical denials, but not how much is still contestable, how much is worth pursuing, or what is at deadline risk.
- Total AR by denial type and payer
- Estimated recoverable amount (conservative/moderate/optimistic)
- Priority appeal sequence by value, deadline, and contestability
- Cases at immediate deadline risk
- Written Denial Recovery Assessment
Aged AR report + denial letter samples. No PHI required at this stage. Converts "we have a denial problem" into "$2.4M aged AR, $680K recoverable, 12 cases closing in 30 days."
Every new engagement starts here. Hospital CFOs, VPs of Revenue Cycle, Case Management Directors.
Deadline risk: cases may be forfeiting appeal rights while they sit in aged AR.
Observation vs inpatient disputes, short-stay denials, and MA retrospective denials remain the highest-volume clinical revenue threat.
- Clinical reconstruction at admission
- MCG / InterQual criteria pathway mapping
- Two-Midnight Rule analysis
- Comorbidity burden documentation
- Peer-reviewed literature support
- ERISA / regulatory arguments
- Observation vs. inpatient disputes
- Short-stay denials
- MA retrospective denials
- Commercial concurrent/retrospective
- RAC/MAC audits
- Inpatient psych, complex surgical
6–12 page physician-authored structured appeal with clinical reconstruction, criteria mapping, and escalation-ready argument architecture. Immediately submittable at any appeal level.
Paid-but-downgraded claims never appear in denial dashboards. They are systematically overlooked even though they are among the most recoverable clinical revenue disputes.
- Physician-level chart reconstruction
- Clinical severity extraction: labs, vasopressor MAR, nursing acuity, vent records
- AHA Coding Clinic-aware argument framing
- Payer auditor rebuttal point by point
- 870 vs. 871 — Sepsis ($10K–$25K)
- 291 vs. 293 — Heart Failure ($4K–$8K)
- 003 vs. 004 — ECMO/Trach ($20K–$40K)
- 460 vs. 461 — Spinal Fusion ($6K–$12K)
- 329 vs. 331 — Major Bowel ($8K–$15K)
- 025 vs. 027 — Craniotomy ($12K–$20K)
Any hospital with paid-but-downgraded claims in sepsis, heart failure, respiratory failure, or complex surgery. CFOs who suspect DRG leakage. RCM companies needing physician-level DRG dispute capacity.
Specialty denials turn on scientific evidence architecture, payer policy, and patient-specific contraindication logic that most billing departments cannot construct.
- NCCN Category designation for indication and therapy line
- Compendia citations with evidence grades
- Patient-specific Phase II/III trial data
- Contraindication extraction for step-therapy dispute
- Specialty society guidelines (ASCO, ACC, AHA, AANS)
- Oncology ($15K–$80K+)
- Cardiology ($20K–$150K+)
- Orthopedics ($20K–$120K+)
- Neurology ($30K–$80K+)
Physician-authored evidence-based appeal with full 5-layer architecture. IMR-ready when required. See for case-level depth.
What Clinovian does not accept
- Administrative denials (eligibility, coding errors, authorisation failures)
- Workers compensation claims
- Medicaid denials
- Medicare fee-for-service denials
- Claims below minimum value thresholds
- Cases requiring U.S. court representation or legal filings
- Cases where documentation correction — not clinical argument — is the rate-limiting factor
Why this matters
Selectivity preserves the standard. Every case is reviewed and authored by the founding physician. Quality is not delegated. Clinovian handles fewer cases than a volume operation — the goal is stronger case selection and cleaner physician-authored submissions.
Key payers accepted: Medicare Advantage (UnitedHealth, Humana, Aetna, BCBS MA), RACs, MACs, commercial payers on high-cost admissions and specialty claims.
A redacted, brand-stamped sample appeal letter demonstrating Clinovian's criterion-by-criterion evidence mapping methodology will be available here soon.
| Service | Use case | Typical structure |
|---|---|---|
| Clinical Denial AR Audit | First-pass portfolio triage without PHI | Fixed fee or complimentary for qualified portfolios |
| P2P Preparation | Urgent payer medical-director call | Flat urgent fee |
| Single Complex Denial | High-value medical necessity, DRG, or specialty denial | Per-case fee based on complexity and claim value |
| NSA / IDR Dossier | Out-of-network dispute requiring arbitrator-facing clinical narrative | Per dispute or batch arrangement |
| RCM Partner Support | White-label physician-authored escalation capacity | Monthly, batch, or per-case model |
Final pricing depends on case complexity, deadline posture, claim value, and volume. The AR Audit is used to decide whether deeper work is economically justified.
The practical differences are rooted in background and method.
The table below is not a slogan. It describes practical operational differences between a generalist service and a physician-led clinical consulting practice built around direct payer review experience.
How to read this: each row addresses a practical question that hospital systems, physician groups, and RCM partners typically raise when evaluating clinical denial support — who authors the appeal, how the denial letter is interpreted, what evidence architecture is applied, and whether the service is capable of operating at IMR, DRG, P2P, and concurrent-review depth.
| Dimension | Standard RCM Vendor | Generalist Consultant | Hospital Physician Advisor | Clinovian |
|---|---|---|---|---|
| Core identity | Administrative billing operation | Clinical writing service | Internal UM support | Physician-led clinical intelligence with payer-insider architecture |
| Payer-side experience | None | None | None | Founding physician served as UM reviewer inside a major U.S. commercial payer |
| Criteria knowledge | Awareness only | Academic familiarity | Treating perspective | Operational knowledge of how MCG/InterQual are applied in real review |
| Appeal construction | Template letters | Physician narrative | Validation memos | Criterion-by-criterion evidence mapping with record-based support |
| Denial letter interpretation | Reads the letter | Reads the letter | Reads the letter | Identifies the applied criteria path and whether correctly used |
| DRG dispute capability | Coding focus | Clinical narrative | Usually out of scope | Full chart reconstruction tied to severity logic and coding guidance |
| Specialty evidence | Cannot produce | General literature | Usually out of scope | NCCN, compendia, patient-specific trial evidence, contraindication extraction |
| Step-therapy disputes | Flags non-compliance | Explains rationale | Not in scope | Exception logic from chart-extracted contraindications and payer criteria |
| Regulatory integration | Minimal ERISA awareness | None | None | ERISA procedural logic integrated into the clinical document |
| P2P preparation | None | Generic support | Variable | Applied criteria path, chart evidence, counterarguments, fallback arguments |
| IMR preparation | Cannot produce | Generic submission | Not in scope | Physician-authored, external-review-ready evidence package |
| Concurrent review | Not in scope | Not in scope | General guidance | Payer-insider guidance on what documentation must exist before tomorrow's review |
| DRG downgrade ID | Not identified | Not in scope | Not in scope | Identifies paid-but-downgraded claims invisible in denial dashboards |
| Case selectivity | All volume | Varies | All internal cases | Minimum thresholds — only cases where physician intelligence changes outcome |
| Document quality | Form letters | Variable narrative | Internal memos | Physician-authored structured argumentation signaling categorical difference |
| RAC/MAC defense | Documentation response | Support narrative | Not in scope | Physician-level extraction plus audit-aware escalation through ALJ |
| Engagement start | Contract first | Contract first | Monthly retainer | Clinical Denial AR Audit first |
| White-label | Sometimes | Sometimes | Not possible | Yes — physician escalation layer for RCM companies |
| NSA IDR dossier | Portal filing only, no clinical dossier | Generic submission | Not in scope | Physician-authored dossier addressing all six statutory additional circumstances — the only variable within provider control |
Clinical categories where the outcome depends on the quality of the evidence architecture.
These are the specialty environments where payer criteria logic and clinical evidence depth interact in ways that standard billing support cannot address. The case typologies below reflect patterns that appear repeatedly in high-value denial portfolios.
- Off-label biologic denials (pembrolizumab, nivolumab, atezolizumab)
- Step-therapy enforcement
- CAR-T and targeted therapy access (KRAS/EGFR/ALK agents)
- Patient-specific appropriateness challenges
- NCCN Category 1/2A/2B for specific indication and line of therapy
- Compendia evidence grading (Drugdex, Clinical Pharmacology)
- Patient-specific Phase II/III trial data matching molecular subgroup
- State step-therapy reform law exception
California IMR overturns approximately 60% of oncology denials when properly submitted.
An oncology group carrying 8 denied biologic authorization cycles over 4 months — average $24,500 per cycle — where 6 of 8 denials applied step-therapy logic that could be defeated by documented contraindication to the required prior agent present in the chart.
- PCI in stable CAD — Appropriate Use Criteria disputes
- ICD/CRT implant — MA vs. traditional Medicare criteria
- AFib ablation and EP procedure denials
- TAVR authorization challenges
- ACC/AHA Appropriate Use Criteria classification
- Hemodynamic and imaging severity support
- Contraindication evidence for antiarrhythmic step logic
- MA criteria vs. traditional Medicare comparison
A cardiology group with 5 denied ICD/CRT implants over 3 months — average $42,000 per case — where the payer applied MA-specific criteria more restrictive than ACC/AHA guidance and traditional Medicare coverage.
- Spinal fusion conservative-treatment disputes
- Total joint replacement severity challenges
- Inpatient vs outpatient classification
- Revision surgery denials
- Conservative treatment failure chronology
- Radiographic severity mapped to threshold (Kellgren-Lawrence, ODI, KOOS, HOOS)
- Comorbidity-driven inpatient monitoring necessity
- CMS THA/TKA inpatient-only removal (2020) argument
An orthopedic surgery center with 12 denied spinal fusions over 6 months — average $38,000 per case — where conservative treatment failure documentation existed in 11 of 12 charts but was never assembled into a chronology.
- MS biologic access (ocrelizumab, natalizumab, ofatumumab)
- Step-therapy enforcement — platform therapy requirement
- Epilepsy device disputes (VNS/RNS)
- SMA therapeutics (Spinraza, Zolgensma, Evrysdi)
- High-efficacy vs. platform therapy data: 60–70% vs ~30% relapse reduction
- JCV antibody index risk stratification for natalizumab
- AAN guidelines supporting high-efficacy induction in high-activity MS
- Real-world evidence where RCT data limited by prevalence
A neurology practice carrying 4 denied high-efficacy MS biologic authorizations — average $68,000 per cycle — where the payer enforced step-therapy despite documented disease activity on prior platform therapy and AAN guideline support.
A 180-bed community hospital with a sustained pattern of DRG 870 vs. 871 disputes — average claim delta of approximately $14,200. Physician chart review in cases of this type typically establishes vasopressor documentation satisfying MCC criteria in the substantial majority of cases. The limiting factor is not the clinical record — it is whether the record has been properly extracted and mapped to the relevant criterion.
An oncology practice with a pattern of off-label biologic authorisation denials across multiple Medicare Advantage plans — average cycle value approximately $31,000. Where the same step-therapy logic is applied across multiple denials, a single properly constructed contraindication argument resolves the pattern rather than each case individually.
An RCM company with hospital clients generating complex clinical denials above internal physician-review capacity. The model in this context is Clinovian operating as a physician escalation layer — the RCM company manages the client relationship; Clinovian provides the clinical argument. White-label and co-branded structures are available.
The above are illustrative composite profiles reflecting the type of cases Clinovian is designed to address. They are not verified outcome reports from specific engagements.
The arbitrator decides based on what is submitted. Nothing else.
Under the No Surprises Act, the Independent Dispute Resolution process gives providers a statutory path to recover out-of-network payment above payer-proposed rates. The arbitrator can only consider what each party submits. The quality of the clinical dossier is the only variable entirely within the provider's control.
Every statutory factor addressed, every arbitrator concern anticipated. Submission-grade.
An arbitrator under 45 CFR § 149.510 reviews dossiers from both parties in under 30 business days and selects one offer — no middle ground. What is submitted is what is decided on.
The specimen below demonstrates Clinovian's full-stack methodology on a batched emergency medicine dispute: $6,800 billed, $1,650 QPA offer, $5,780 provider offer. Eleven pages covering procedural compliance, a six-vector QPA credibility rebuttal, all six statutory additional circumstances, Brookings/CMS benchmarking, a quantitative justification chain, and seven indexed exhibits.
The No Surprises Act created a federal arbitration right. Most providers are not using it fully.
The No Surprises Act (NSA), effective January 2022, prohibits balance billing for emergency services, non-emergency services at in-network facilities from out-of-network providers, and air ambulance services from OON providers. When an insurer's payment on an OON claim falls below what the provider believes is appropriate, the provider can initiate Independent Dispute Resolution.
IDR is a federal arbitration process administered through the FEMA portal. A certified arbitration entity reviews submissions from both sides and selects one of two offers — the provider's or the insurer's. There is no split-the-difference outcome. The arbitrator chooses one offer in its entirety.
The constraint most providers do not understand: the arbitrator cannot investigate independently. They cannot pull additional records, call the provider, or research the market. They can only evaluate what each party submits. This is why the quality of the dossier is the entire variable.
The gap: five PE-backed groups account for roughly 60% of all IDR filings. Tens of thousands of smaller independent practices — emergency medicine groups, radiologists, anaesthesiologists, surgical centers — have IDR-eligible claims they are not pursuing because they lack the clinical argumentation infrastructure. That is the buyer Clinovian serves.
What the arbitrator is required to consider — and what is strictly prohibited.
The NSA defines what information the IDR entity must consider, what additional circumstances may be considered, and what information is excluded. Understanding this structure is the prerequisite to building a credible dossier.
The Qualifying Payment Amount (QPA)
The QPA is the insurer's calculated 2019 median in-network contracted rate for the same or similar service in the same geographic region, indexed for inflation. It serves as the anchor of the arbitration.
The arbitrator must presume that the QPA represents the appropriate out-of-network rate unless the submitting party provides credible information that the additional circumstances warrant a different amount. This presumption is rebuttable — and that rebuttal is the entire point of a well-constructed dossier.
Current regulatory note: FAQ Part 73 (April 2026) extended enforcement discretion allowing insurers to use the 2021 QPA methodology through at least October 1, 2026. This limits the magnitude of some awards in the near term but does not alter the fundamental process or the role of additional circumstances.
The arbitrator is statutorily prohibited from considering these. Submitting them is wasted space and signals a poorly prepared dossier.
- Usual and customary charges
- Billed charges or chargemaster rates
- Reimbursement rates under Medicare, Medicaid, or TRICARE
Must be considered if submitted by either party
Board certifications, fellowship training, subspecialty qualifications, procedure volume, outcomes data, peer-reviewed publications. The most consistently underutilised factor in small-practice dossiers.
Relative bargaining power in the local market. A provider representing the only subspecialty coverage in a region has leverage. An insurer with dominant market share suppressing competition has exposure. Both are arguable.
The most clinical of all six factors. This is where physician-level reasoning about severity, risk stratification, comorbidity burden, and intervention complexity is directly applicable — and where RCM billing staff have no capacity to construct a meaningful argument.
Particularly relevant for academic medical centers, Level I/II trauma centers, rural critical access hospitals, and facilities with complex or underserved patient populations that justify above-QPA reimbursement.
Evidence that the provider attempted in good faith to participate in-network and was prevented from doing so by the insurer's rate suppression, narrow network construction, or refusal to negotiate.
Historical in-network rates that exceed the QPA are directly relevant. If the insurer previously paid substantially above QPA, submitting that history creates strong pressure on the arbitrator's QPA presumption.
RCM companies handle the portal mechanics. They are not built to construct the clinical argument.
Factor 03 left blank or generic
Acuity and complexity is the most decisive additional circumstance for clinical disputes. Most RCM-prepared dossiers submit a one-paragraph description of the encounter. A physician-authored acuity narrative maps the patient's specific risk stratification, comorbidity burden, intervention intensity, and clinical decision complexity to the arbitrator's evaluation standard. These are structurally different documents.
Factor 01 submitted as a CV attachment
Training and experience is meant to demonstrate why this provider's skill commands above-QPA reimbursement for this category of service. Attaching a curriculum vitae is not the same as constructing a narrative that connects board certifications, procedure volume, subspecialty training, and outcome data to the specific service in dispute. Arbitrators read dozens of submissions. Generic CV attachments do not move decisions.
Prohibited factors submitted anyway
Submitting billed charges or Medicare rates is not just useless — it signals to the arbitrator that the submitting party does not understand the statutory framework. This actively reduces confidence in the rest of the submission. It happens because the person preparing the dossier is familiar with denial appeal language (where those factors are relevant) rather than IDR statute.
No market analysis on Factor 02
Market share data requires regional analysis of insurer and provider concentration. RCM billing staff are not equipped to pull insurance market concentration data, analyse network adequacy, or articulate a geographic market argument. When this factor is omitted, the provider surrenders what can be a significant supporting argument, particularly in underserved regions.
Good-faith network history not documented
Many independent providers have correspondence, rate proposals, and negotiations with the insurer over the past four years that demonstrate good-faith efforts to enter network agreements. This documentation — when it exists — is a statutory factor the arbitrator must consider. It is almost never submitted by small practices because nobody thought to ask for it.
Dossier written for the billing team, not the arbitrator
The certified arbitration entity is reviewing clinical and contractual disputes across dozens of specialties simultaneously. A dossier written in billing-department language, with CPT-code-heavy framing and generic medical necessity assertions, does not read like a document from a party who understands what the arbitrator is evaluating. Physician-authored submissions in clinical-legal argumentation language are structurally distinguishable from the first paragraph.
A physician-authored dossier that addresses every factor the arbitrator is required to consider — in the language arbitrators evaluate.
A structured analysis of the insurer's QPA methodology for the specific service in the specific geographic region. Where the QPA understates true market rates — due to narrow network construction, outdated benchmark data, or methodology errors — this is documented with specificity. This is the foundation every other section builds on.
A physician-authored clinical argument describing the specific acuity of the patient encounter and the complexity of the services rendered. Risk stratification using validated tools, comorbidity burden analysis, intervention-specific complexity, and clinical decision complexity are mapped to the statutory standard. This is the section that differentiates a Clinovian dossier from every RCM submission. It requires a physician who can reason about clinical complexity, not a billing coder who can describe a procedure.
A structured argument connecting the provider's training credentials, fellowship qualifications, subspecialty certifications, procedure-specific volume, and documented outcome data to the question of why above-QPA reimbursement is warranted for this category of service. Not a CV. An argument. The distinction matters to the arbitrator.
Regional market share analysis, geographic access data, facility teaching or trauma status, four-year network negotiation history, and prior contracted rates where applicable. Each factor addressed specifically or explicitly noted as not applicable with reasoning. A dossier that addresses all six factors signals discipline. A dossier that ignores three of them signals inexperience.
Eligibility confirmation
Clinovian reviews the claim, service date, NSA applicability, and filing deadline. Only NSA-eligible OON disputes are accepted. IDR must be initiated before the 30-business-day negotiation period expires.
Document intake
Insurer's initial payment determination, EOB, clinical records relevant to the specific encounter, provider credentialing documentation, and any prior network correspondence. Collected via secure transfer under BAA.
QPA and market analysis
Analysis of the insurer's QPA for the service and geographic region. Regional market concentration and network adequacy review. Identification of prior contracted rate history between the parties where available.
Dossier construction
Physician-authored drafting of all six additional circumstance sections plus the QPA rebuttal. Every section is referenced to the specific case facts. No templates. No generic language. The clinical reasoning is specific to the encounter.
Delivery and filing support
Completed dossier delivered in filing-ready format. Guidance on FEMA portal submission. The provider retains full control over the submission — Clinovian prepares the clinical and analytical substance; the provider or their administrator files.
IDR dossier preparation is designed for the practices most underserved by the current market.
Emergency medicine
The highest-volume IDR category. Independent EM groups treating patients at in-network facilities are OON by definition for a substantial portion of encounters. Most are not filing IDR at scale because they lack clinical argumentation infrastructure — not because their claims are weak.
Radiology & anaesthesiology
Specialties with structural OON exposure at in-network hospitals. The acuity and complexity argument is particularly strong for complex interventional radiology, neuroradiology, and high-acuity anaesthesia management. These arguments require a physician to construct, not a billing department.
Surgery & procedural specialties
Complex surgical procedures — particularly urgent or emergent cases — often involve OON specialists at in-network facilities. Procedure-specific complexity, surgical risk stratification, and subspecialty training arguments are all available and frequently unused.
Cases Clinovian accepts for IDR
- NSA-eligible out-of-network claims for emergency services
- NSA-eligible OON claims for non-emergency services at in-network facilities
- Air ambulance OON claims under NSA coverage
- Claims where the insurer's initial payment is below the QPA or where there is a genuine basis to argue above QPA on additional circumstances
- RCM firm portfolios requiring physician clinical argumentation layer
Minimum claim value: IDR filing fees ($150–$350 per dispute) plus Clinovian's preparation cost are most justified on claims above approximately $2,000. For batched disputes of similar service codes from the same insurer, economies of scale apply.
Cases Clinovian does not accept for IDR
- Claims not covered by the No Surprises Act (Medicaid, Medicare, TRICARE, grandfathered plans)
- Disputes where the sole argument is billed charges vs. payment — without a defensible additional-circumstances basis
- Claims where the IDR initiation deadline has already passed
- Disputes already in litigation or binding arbitration under a separate contractual mechanism
Deadline critical: IDR must be initiated within 30 business days of the end of the open negotiation period. This is a hard deadline. Cases that arrive after expiry cannot be filed regardless of clinical merit.
Why the same clinical-review knowledge that strengthens denial appeals also strengthens IDR dossiers.
The Clinovian thesis has always been that payer-insider knowledge changes the argument. In denial appeals, that knowledge determines which criteria path the reviewer is applying and what evidence is needed to satisfy it. In IDR, that same knowledge determines how the insurer will construct their counter-submission — and therefore what the clinical dossier needs to preempt.
A physician who has reviewed claims from inside a payer's utilisation management department understands the language payer medical staff use to characterise complexity, the framework payer teams use to assess acuity, and the patterns of argument payer counter-submissions typically take. That understanding informs every section of the dossier — not just the clinical narrative, but the framing, the sequencing, and the anticipation of the insurer's response.
- Adversary: payer UM reviewer applying MCG / InterQual
- Task: construct a clinical argument that satisfies the specific criterion the reviewer applied
- Payer-insider advantage: know which criteria path was used and what evidence language satisfies it
- Adversary: insurer constructing a counter-submission favouring QPA
- Task: construct a clinical argument that gives the arbitrator credible grounds to move above QPA
- Payer-insider advantage: know how the insurer will frame complexity and what the arbitrator needs to see to rebut it
What a single well-prepared dossier is worth — in round numbers.
Indicative economics — one OON emergency service dispute
Provider win rate context: 88% of IDR decisions favoured providers in H1 2025 across all dispute types. Not every case reaches arbitration — some settle during open negotiation once IDR is initiated. Both outcomes return above-QPA payment to the provider.
Important framing: the 450% QPA figure reflects 2024 averages across all disputes. Individual awards vary substantially by service category, geographic region, insurer, and dossier quality. Clinovian does not guarantee any outcome. The economics above are illustrative of the opportunity scale, not a projection for any specific engagement.
The IDR process is evolving. Here is the honest picture as of April 2026.
What is stable
- The No Surprises Act is federal law. IDR is the statutory mechanism. Neither is under meaningful legislative threat.
- The six additional circumstances are codified in statute. They cannot be eliminated by regulatory guidance without amending the NSA itself.
- Recent public data has shown strong provider-side selection rates, but every dispute remains fact-specific and no result should be assumed.
- The IDR Operations Final Rule (proposed November 2023, expected finalisation 2026) is expected to make the process more standardised and efficient. Standardisation favours quality submissions over volume-filing.
What is shifting
- FAQ Part 73 (April 2026): enforcement discretion extended to allow 2021 QPA methodology through October 1, 2026. This lowers the ceiling on some awards but does not change the process or the role of additional circumstances.
- PE-backed filer scrutiny: Congressional and regulatory pressure is targeting high-volume PE-backed groups filing IDR at industrial scale. Any reform that increases weight given to clinical quality over volume-filing helps physician-led, quality-first practices. Clinovian's model is directly aligned with the reform direction.
- Batching rules: disputes involving the same insurer, same service code, and same facility in the same 30-business-day period can be batched. Batching rules are evolving but the economics improve substantially with batching.
Risk assessment: moderate regulatory flux with a continuing statutory foundation. The combination of a federal statutory right, a documented high provider win rate, and $2.2B in provider recoveries over 2.5 years constitutes a durable market, not a regulatory arbitrage window.
IDR is the fastest path to a Clinovian engagement.
Per-case. No long-term contract required. Submit one dispute. The arbitrator's determination provides a clear outcome within weeks. If the dossier performs, send more cases. The feedback loop is measurable and fast.
1CMS IDR data releases and ACEP / provider coalition analysis of FEMA portal outcomes, H1 2025. Win rates vary by service category and dispute type. The 88% figure reflects the aggregate provider-selection rate across all NSA IDR disputes decided in H1 2025.
Average award of 450% of QPA reflects 2024 CMS data analysis. Individual awards vary substantially by service, region, and insurer. Clinovian makes no guarantee of outcome on any individual dispute.
$2.2 billion recovery figure per ACEP and provider coalition analysis of cumulative IDR outcomes through mid-2024 relative to applicable in-network rates.
Regulatory references: FAQ Part 73 (April 2026), NSA IDR Operations Final Rule (proposed November 2023), No Surprises Act 15 U.S.C. § 300gg-111.
Clinical observations on the denial and appeal process.
Each article draws on operational experience with payer review logic, clinical criteria application, and the mechanics of how denials are issued and sustained — with the intention of being practically useful to physician advisors, case management teams, and revenue cycle leaders.
The Two-Midnight Rule remains the backbone of many inpatient level-of-care disputes. The rule does not require that the patient stayed two midnights. It requires that the admitting physician's expectation of a two-midnight stay was reasonable and documented at the time of admission.
Most failed appeals argue clinical severity in general terms without reconstructing the admission-time expectation logic that satisfies the rule's actual standard. The dispute is whether the documented clinical picture at admission made a two-midnight expectation reasonable and defensible.
Downgrade patterns are rarely random. The same DRG pairs — sepsis 870/871, heart failure 291/293, craniotomy 025/027 — are targeted repeatedly because the same documentation vulnerabilities recur. Payer auditors know which pairs have the highest probability of successful downgrade, and they audit those categories systematically.
DRG downgrades appear as paid claims — not denials. They are invisible in denial dashboards. A hospital can have $400K+ in annual DRG downgrade leakage with no visibility because reporting infrastructure was built for zero-pay denials, not partial-pay disputes. Clinovian's AR Audit specifically identifies these.
MCG operates on objective severity markers — vital sign thresholds, lab ranges, clinical findings with timestamps. InterQual uses a subset system requiring specific intervention language. The reviewer pulls the criteria path and checks for explicit evidence. If documentation does not match the specific criterion, denial is issued.
Most failed appeals contain a clinical rationale but no direct criteria mapping. The provider sends a letter explaining why the patient needed care. The reviewer reads it against the specific criterion pathway. Because the letter never addresses that pathway, the reviewer stamps "no new information."
It costs a payer $25–$50 to issue a denial algorithmically. It costs a hospital $181 to rework a single complex case. When 65% of denials are never appealed and the overturn rate when properly contested is 57–80%, the payer captures roughly 65% of denied revenue permanently with near-zero marginal cost. The system is designed around provider surrender.
A 200-bed hospital generating 80–120 clinical denials/month at $17K–$25K average carries $1.36M–$3.0M in monthly at-risk revenue. If internal staff appeals 15–25% at 20–35% success, current recovery is ~5–8% of at-risk revenue. Physician-level intervention raises success to 54–80% — estimated additional monthly recovery: $350K–$800K. Most of that delta is currently written off.
ERISA establishes procedural requirements the payer must follow — specific response timelines, plan document consistency, and disclosure obligations. When violated, these create independent appeal arguments entirely separate from clinical merits. Most providers never raise them because they treat the appeal as purely clinical.
ERISA preempts state insurance law for employer-sponsored plans. For state-regulated plans, state-level IMR rights often provide stronger protections. Understanding which framework governs the plan determines which escalation path has the highest probability of success and which procedural arguments are available.
RACs and MACs issue Additional Documentation Requests (ADRs) targeting specific claims for post-payment review. The hospital has 45 days to respond. Most hospitals respond by sending the chart. This is not a defense — it is a submission. Raw documentation without a structured physician-level argument built around the auditor's specific challenge is why most RAC disputes result in recoupment.
RAC/MAC disputes follow Redetermination → QIC Reconsideration → ALJ. Each level requires a differentiated argument. Clinovian constructs the initial response with the full escalation architecture in mind, building the administrative record that will be evaluated at ALJ. AHA Coding Clinic citations, clinical literature, and payer auditor rebuttal — point by point — are standard.
Operational references drawn from direct payer review experience. Each document is designed to be used at the desk, not read once and filed.
Physician Appeal Letter — Inpatient Medical Necessity, MCG Misapplication
A full illustrative appeal for a $27,450 urosepsis inpatient denial. Criterion-by-criterion MCG ISC mapping with timestamped evidence, pathway-misapplication argument, 29 CFR § 2560.503-1 procedural grounds, guideline literature, and a specific monetary remedy. Includes a toggle for methodology annotations explaining why each section is engineered to win on those exact points.
Federal IDR Dossier — No Surprises Act Arbitration Submission
An illustrative 11-page arbitrator-facing dossier for a $6,800 batched emergency medicine dispute. Procedural compliance declaration, six-vector QPA credibility rebuttal, all six statutory additional circumstances under 45 CFR § 149.510, Brookings/CMS benchmarking with prevailing-offer positioning, quantitative offer justification chain, and seven indexed exhibits (A–G). Navy-framed federal arbitration format.
Appeal Deadline Reference
Filing windows by payer type and appeal level — commercial, Medicare Advantage, external review, RAC/MAC, state IMR, and ALJ.
Peer-to-Peer Preparation Checklist
A practical working checklist for scheduled P2P calls. Interactive — check items off as you work through them.
What to Send for an AR Audit
Clean intake reference for hospitals, specialty practices, and RCM partners. Reduces back-and-forth in the first 72 hours.
DRG Downgrade Priority Reference
The six highest-yield DRG dispute pairs — typical revenue delta, payer's argument, and the specific evidence that counters it.
MCG vs. InterQual: Operational Differences
How each criteria set is actually applied in payer review — where the logic differs and where appeals fail for each.
Two-Midnight Rule Cheat Sheet
Admission-time expectation logic, documentation requirements, and the most common errors in appeals filed under this rule.
Clinovian is built around a physician authorship standard — with a deliberate review bench architecture behind it.
Clinovian is a physician-led clinical intelligence firm serving U.S. providers, RCM partners, and facility groups on high-value medical necessity denials, DRG integrity disputes, specialty clinical denial portfolios, and No Surprises Act Independent Dispute Resolution. The firm exists to recover revenue in the specific cases where the rate-limiting factor is not administrative throughput or coding cleanup, but physician-grade clinical argument.
Clinovian operates on a single authorship standard: every submission is authored and reviewed by a licensed physician against a codified review discipline — the operational logic of MCG and InterQual application, the documentation patterns that separate approved cases from sustained denials, the criterion paths reviewers recognise and the ones they miss. That standard is the product. It is not a lone-physician craft, and it does not depend on any single individual on the bench.
An authorship standard — codified, taught, supervised.
The firm's review discipline is a codified standard developed by Clinovian's founding physician, drawing on direct U.S. commercial payer utilisation management review experience. It is institutionalised as the benchmark to which every contributing physician on the authorship bench is trained — and the standard against which every outgoing submission is measured.
Clinovian's founding physician has, in prior engagements, trained and supervised utilisation management reviewers at scale. That experience is the operational basis for the firm's onboarding methodology: physicians are brought onto Clinovian's authorship bench to a defined review standard, not a general clinical competence threshold. The discipline — not any individual's signature — is what reaches the payer.
Review bench — current composition, structured expansion.
At current engagement volume, case authorship flows primarily through the firm's founding physician, with every submission passing a second-physician review before transmission. The bench is structured to expand in step with engagement volume — without compromising the authorship standard on any individual case.
The firm maintains a vetted pool of U.S.-licensed and India-trained physicians whose clinical argumentation has been individually reviewed against Clinovian's standard. Additional reviewers are onboarded as engagement volume requires. For organisations with sustained higher-volume needs, two channels scale the bench responsibly: a Physician Advisory retainer with a named Clinovian physician assigned to the engagement, and white-label partnership structures in which the firm operates as a physician escalation layer within an existing RCM framework.
Payer-Side Review Experience
Direct utilisation management reviewer practice inside a U.S. commercial payer — operational MCG and InterQual application, not theoretical familiarity.
Medico-Legal Precision
Medico-legal training on the bench informs appeal and IDR submissions as structured clinical-legal briefs. Regulatory and procedural context is organized only to support the clinical argument; legal strategy and filings remain with client counsel.
Criterion-Level Evidence Mapping
Every submission maps the specific criterion cited in the denial to the specific data point in the medical record. Structured evidence extraction, not clinical narrative, carries the weight.
Full Escalation Readiness
Every document is constructed with the complete appeal or arbitration hierarchy in view. Level 2, IRO, and NSA/IDR submissions are engineered at the moment of initial authorship, not retrofitted.
photo
slot
Replace with professional portrait before large-scale outreach.
Arun Kasturi, MBBS, LLB
Clinovian's founding physician brings direct U.S. commercial payer utilisation management review experience — daily MCG and InterQual application under operational conditions — together with prior experience training and supervising utilisation management reviewers at scale. The law qualification alongside the medical degree is the basis for the firm's medico-legal precision in appeal letter and IDR dossier construction.
Verification details. LinkedIn profile, registration/entity details, BAA, and procurement documents are available to qualified prospects during onboarding.
How we engage. Clinovian onboards through a no-PHI Clinical Denial AR Audit (for denial portfolios), a per-case NSA/IDR Dossier (for out-of-network payment disputes), or a Physician Advisory retainer (for sustained concurrent-review needs). Every engagement begins with a written scope and a review by a Clinovian physician — no intake proceeds to case authorship without clinical eyes on it first.
Start with a Clinical Denial AR Audit.
The audit is the fastest way to convert an abstract denial problem into a quantified recovery opportunity. It shows what is contestable, what is recoverable, and what may already be at deadline risk — in 72 hours.
Urgency: most commercial payer internal appeal deadlines run 60–180 days from denial date. Medicare Advantage: 60 days. Cases in your current AR may be forfeiting their appeal right permanently while you evaluate options.
Aged AR report, payer names, denial dates, sample denial letters. No PHI required at this stage.
Physician-level triage: contestability, recoverable value, priority sequence, deadline risk.
Written Denial Recovery Assessment with next-step recommendations. Engagement formalised only if recovery justifies it.
Select the appropriate service below
Each intake form is purpose-built for its engagement type. The public website does not process clinical records. Initial forms are no-PHI. PHI is accepted only after scope approval, client BAA, access controls, and secure transfer workflow are in place.
Clinical Denial AR Audit
72-hour physician triage of aged clinical denial AR. No PHI required — submit your AR report and sample denial letters only.
Single Complex Denial
One high-value inpatient necessity, DRG integrity, or specialty clinical denial requiring physician-level appeal construction.
Peer-to-Peer Preparation
Physician briefing document for a scheduled call with a payer medical director. Time-sensitive — submit as early as possible.
Physician Advisory
Ongoing payer-facing physician support — concurrent review, P2P coverage, and documentation guidance for hospital UM teams.
RCM Partnership Inquiry
For RCM companies that want physician-authored clinical escalation as a white-label, co-branded, or referral layer.
No Surprises Act IDR Support
Clinical dossier preparation for NSA Independent Dispute Resolution proceedings. Includes all six statutory additional circumstances, QPA analysis framework, and arbitrator-facing evidence architecture.
Select a service above to continue
Email: contact@clinovian.com
Schedule a call: calendly.com/clinovian/30min →
Email-first for security and traceability. Calendar holds available for qualified prospects. Responses within one business day.
This practice serves: hospital revenue cycle and case management leadership, specialty practice administrators, CFOs evaluating clinical denial exposure, and RCM companies requiring physician escalation capacity.
What to send first
- Aged AR extract with identifiers removed
- Payer, plan type, denial reason, claim value
- Denial date and appeal deadline if known
- De-identified sample denial rationale
- Current appeal level and service line
Who should not use this intake
- Patients seeking medical advice
- Low-value administrative denials
- Routine eligibility, registration, or COB issues
- Bulk claims calling or payment posting needs
- Matters requiring U.S. legal representation
How clinical information is handled at each stage.
No PHI at this stage
The AR Audit is conducted on aged AR reports and denial letter samples only. No protected health information is required or requested. Submissions at this stage are received via Clinovian's Google Workspace environment under an executed Google Business Associate Agreement.
Separate secure transfer workflow
When clinical record access is required for appeal construction, Clinovian provides a secure BAA-governed transfer workflow. PHI is never transmitted via standard email. A signed client BAA and written scope are in place before any PHI is accessed. Clinovian operates from India; cross-border processing is disclosed and handled under client-approved contractual safeguards.
Physician-authored documents only
Clinovian's deliverables are structured written documents — appeal letters, briefing packages, and assessment reports. These contain only the clinical information necessary to support the specific dispute. They are returned via the same secure transfer channel used for intake and do not contain unnecessary PHI.
BAA and workflow documentation
Organisations requiring a copy of Clinovian's executed Google BAA, a data processing summary, or detailed information about the secure transfer workflow before proceeding may request these at contact@clinovian.com.
Proof assets that make the service tangible.
Before a provider shares PHI or commits to a larger engagement, they should be able to inspect the quality of the clinical argument. These specimen documents show the format and level of reasoning Clinovian produces.
Sample physician appeal
A specimen inpatient medical-necessity appeal showing how clinical facts are mapped to the denial pathway and reviewer decision logic.
Specimen recovery assessment
A sample 72-hour no-PHI AR audit report showing recoverable inventory, deadline risk, payer patterns, and recommended pursuit sequence.
Sample IDR dossier
A specimen federal IDR dossier showing clinical complexity narrative, QPA response structure, and statutory factor mapping.
The key asset is not polished language. It is structured clinical argument mapped to payer decision logic.
The samples may reference regulatory or procedural context, but Clinovian provides clinical consulting only.
The documents are illustrative and use specimen data. Real case work begins only after secure intake and appropriate agreements.
Clinical Denial AR Audit Report.
This sample shows what a provider receives after the no-PHI 72-hour review: recoverable AR, priority sequence, deadline risk, payer pattern analysis, and recommended next actions.
Specimen Clinical Denial Recovery Assessment
Illustrative sample only · No PHI · Fictional denial inventory · Prepared to demonstrate deliverable structure
Executive readout
The reviewed denial inventory contains a concentrated recovery opportunity in inpatient medical necessity, DRG downgrade, and specialty authorization denials. The strongest first-wave cases are not necessarily the highest-dollar claims; they are the cases where claim value, evidence strength, payer pattern, and deadline proximity overlap.
| Bucket | Denied AR | Contestable estimate | Primary issue | Recommended action |
|---|---|---|---|---|
| Inpatient medical necessity | $1,120,000 | $410,000 | MCG / InterQual level-of-care dispute | Physician-authored appeal package |
| DRG downgrades | $520,000 | $145,000 | Secondary diagnosis and severity logic | DRG recovery argument with clinical support |
| Specialty denials | $460,000 | $95,000 | Medical necessity and authorization mismatch | Targeted specialty appeal |
| Low-yield administrative | $300,000 | $30,000 | Missing administrative data or non-clinical reason | Do not assign physician time unless deadline-protected |
Priority sequence
| Priority | Case type | Claim value | Deadline posture | Reason to pursue first |
|---|---|---|---|---|
| 1 | Inpatient sepsis denial | $78,400 | 9 days remaining | High acuity indicators and imminent forfeiture risk |
| 2 | Cardiology inpatient downgrade | $64,200 | 14 days remaining | Objective monitoring intensity appears under-argued |
| 3 | DRG downgrade — respiratory failure | $42,900 | 28 days remaining | Clinical severity markers support higher-weighted DRG argument |
| 4 | Specialty infusion denial | $31,600 | 35 days remaining | Policy exception argument likely available from chart pattern |
Operational recommendation: file deadline-protective appeals on the first 14 cases before pursuing lower-dollar inventory. Do not spend physician time on low-yield administrative denials unless contract deadlines require preservation.
Send AR first. No PHI required.
The goal is to prove recovery potential before deeper record review.
Built to reduce trust friction before any record review.
Clinovian's first step is deliberately no-PHI. Clinical records are requested only after the scope, agreement, BAA, and secure transfer workflow are in place.
No-PHI AR Audit
Initial review uses aged AR, payer names, denial dates, denial categories, and sample denial letters. Protected health information is not requested for the first audit.
BAA before records
Clinical records are requested only after a defined work scope and Business Associate Agreement are in place.
Secure transfer only
PHI is not sent through ordinary email. Record transfer occurs through a secure workflow provided after engagement approval.
Minimum necessary
Only the clinical information needed for the specific denial, appeal, P2P brief, or dossier is reviewed.
India-based processing disclosed
Clinovian operates from India. Cross-border processing is disclosed and handled through contractual safeguards and client-approved workflow.
Clinical consulting only
Legal strategy, filing decisions, and jurisdiction-specific advice remain with client counsel or the client’s designated legal representative. Regulatory context is used only within clinical appeal environment analysis.
Do not do this
Do not email full charts, PHI, patient identifiers, medical records, or claim packets before a formal workflow is established.
Do this first
Send a de-identified or no-PHI aged denial AR extract with payer, denial type, denial date, claim value, and sample denial rationales.
Security and PHI handling, laid out as a buyer-review checklist.
Google BAA + client BAA
Clinovian uses HIPAA-eligible Google Workspace services under an executed Google BAA. Client PHI is accepted only after a client BAA and written scope are in place.
Minimum necessary
Access is restricted to personnel assigned to the engagement. MFA, role-based access, and document-level permissions are used for PHI workflows.
Traceable workflow
Email-first intake, access logs, version-controlled files, and documented transfer links support traceability for compliance review.
In transit and at rest
Files are handled through encrypted transfer and storage workflows. PHI is not accepted through the public website or ordinary intake page.
No PHI in public AI tools
PHI is not entered into public or non-BAA AI systems. Any AI-assisted non-PHI workflow is limited to de-identified, non-patient-identifying material.
Delete or retain by SOW
Retention and deletion are defined in the statement of work or BAA. Default position: keep only what is needed for the engagement and delete upon agreed instruction.
Disclosed before PHI
Core infrastructure relies on HIPAA-eligible Google Workspace. Any additional subprocessor or transfer mechanism is disclosed before PHI workflow approval.
Notice workflow
Potential incidents are escalated through the BAA-defined notification workflow, with investigation, containment, and client notification obligations documented in the agreement.
India-based processing
Clinovian operates from India. Cross-border processing is disclosed upfront and only proceeds through client-approved contractual safeguards.
Trust shouldn't be asserted — it should be linkable.
Below are the third-party references and standards that govern Clinovian's PHI handling workflow. Compliance officers reviewing this engagement can verify each independently.
HIPAA-eligible service tier
Clinovian uses HIPAA-eligible Google Workspace services under an executed Google BAA. This is one control layer; full HIPAA compliance also depends on the client BAA, access controls, safeguards, and workflow discipline.
Google HIPAA documentation →HIPAA Privacy & Security Rules
Clinovian structures PHI handling around BAA, minimum-necessary access, breach-notification, and security-safeguard expectations described by HHS Office for Civil Rights guidance.
HHS HIPAA portal →Sample BAA available on request
A redacted Clinovian BAA template is available for compliance review prior to scope finalisation. Email-request only; circulated under NDA.
Request BAA template →SOC 2 status. Clinovian is not currently advertising SOC 2 certification. If a SOC 2 programme is initiated, the auditor and report date will be published here when complete. Until then, buyers should evaluate Clinovian through BAA terms, security fact sheet, secure transfer workflow, minimum-necessary access controls, and documented operating procedures.
Procurement-ready answers for PHI handling, AI use, cross-border processing, and BAA workflow.
This page is written for compliance officers, RCM leaders, and procurement teams reviewing Clinovian before any record transfer.
Procurement packet available on request
For qualified prospects, Clinovian can provide a review packet covering the client BAA, security fact sheet, draft SOW, data-handling procedure, cross-border processing disclosure, and service-specific sample deliverables.
- Business Associate Agreement template
- Security and PHI-handling fact sheet
- Service-specific statement of work
- AI-use and de-identification policy
- Retention/deletion procedure
- Subprocessor and transfer workflow disclosure
Plain-English PHI boundary
Clinovian does not request PHI for the first AR Audit. If a deeper engagement proceeds, PHI is accepted only after scope approval, BAA execution, access controls, and secure transfer setup.
No public-AI PHI policy: PHI is not entered into public or non-BAA AI tools. De-identified, non-patient-identifying material may be used for drafting, formatting, or internal workflow support where appropriate.
HIPAA-eligible Google Workspace
Used under executed Google BAA. Client-specific PHI workflow still requires client BAA, scope, and access-control approval.
No PHI through public website
Website and first AR Audit are no-PHI. Clinical records are transferred only through secure workflow after engagement approval.
Assigned-case access only
Only personnel assigned to the engagement receive access to the relevant file set, consistent with minimum-necessary review.
Required for PHI workspace
Accounts used for sensitive workflows require multi-factor authentication and controlled access.
Access and version traceability
Workspace controls and email-first intake preserve traceability for file access, transfer, and version history.
Encrypted transfer/storage
PHI is handled through encrypted transfer and storage workflows; unencrypted ordinary-email record exchange is not used for clinical record packets.
Defined in SOW/BAA
Retention periods, deletion triggers, and client retrieval/deletion requests are documented in the engagement terms.
BAA-governed notification
Security incidents are handled under the notification, investigation, mitigation, and cooperation terms of the BAA.
Disclosed India-based processing
Processing from India is disclosed before PHI transfer and governed by client-approved contractual safeguards.
Add physician-authored denial escalation without hiring physicians.
Clinovian can operate as a white-label or co-branded clinical argument layer for RCM companies that already manage denials but need physician-grade appeal construction for high-value cases.
Why RCM firms use Clinovian
- Protect the client relationship while expanding recovery capability
- Escalate only the denial cases where physician argument can change outcome
- Avoid hiring full-time physicians for inconsistent denial volume
- Offer premium clinical appeal support under your existing account structure
How the workflow fits
Your team flags high-value clinical denials.
Clinovian prepares the physician-authored argument.
You deliver the appeal as white-label, co-branded, or specialist add-on.
Operate behind your existing brand
Best when your RCM company owns the hospital/client relationship and prefers Clinovian to operate as an unbranded clinical escalation layer.
Physician specialist layer
Best when the client values visible physician involvement and specialist credibility.
Case-by-case escalation
Best when you want to refer out complex denials without building the workflow internally.
Use Clinovian as your clinical escalation layer.
Start with a small batch of cases and evaluate recovery quality before committing volume.
Privacy Policy
This website is intended for business inquiries and professional communications. Please do not submit patient-identifying information or protected health information through unsecured channels unless and until Clinovian directs you to an approved secure workflow.
Overview
Clinovian provides clinical consulting and physician advisory services related to clinical denials, utilisation review, revenue integrity, and related healthcare operations support. This Privacy Policy explains how we collect, use, disclose, and protect information when you visit our website, contact us, submit an intake form, request information, or otherwise interact with us.
This policy does not create a Business Associate Agreement and does not replace any separate contractual privacy, security, or data processing terms that may apply to a specific client engagement.
Scope
This Privacy Policy applies to information collected through the Clinovian website, contact and intake forms, email and other communications, downloadable resources, newsletters, and related site features.
Information We Collect
Information you provide
- Name, organisation name, title, email address, and telephone number
- Inquiry and intake details relating to denial categories, appeal timelines, payer types, service needs, and related operational context
- Documents voluntarily submitted through designated intake workflows
Technical and usage information
- IP address, browser type, and device type
- Referral source, pages visited, and approximate location based on IP address
- Website interaction and analytics data
Newsletter and resource activity
If you subscribe to updates, download a resource, or request information, Clinovian may collect your contact details and related interaction history.
How We Use Information
- Respond to inquiries and evaluate potential engagements
- Provide requested services and communications
- Route intake requests internally
- Improve website content, structure, and user experience
- Send newsletters, updates, or resource materials where requested or permitted
- Protect the security and integrity of our website and systems
- Comply with legal, regulatory, contractual, and risk-management obligations
Legal bases
Depending on context and applicable law, Clinovian may process information based on consent, performance of a contract or pre-contract steps, legitimate business interests, and compliance with legal obligations.
How We Share Information
Clinovian does not sell personal information. We may share information with:
- Service providers supporting hosting, intake processing, analytics, communications, and document management
- Professional advisers including legal, compliance, accounting, and insurance advisers
- Authorised personnel and contractors who require the information for legitimate business purposes
- Regulatory authorities or courts where required by law or regulatory process
- Acquirers in connection with a merger, acquisition, restructuring, financing, or sale of assets, subject to appropriate protections
Where a third party handles information on our behalf, we expect appropriate confidentiality, security, and data-handling safeguards to be maintained.
Cookies and Analytics
Clinovian may use cookies, similar technologies, and analytics tools to understand website performance and user behaviour. You can control cookies through your browser settings. Disabling cookies may affect certain website features.
Data Retention
Information is retained for as long as reasonably necessary to respond to inquiries, maintain business records, perform services, comply with contractual and legal obligations, resolve disputes, and enforce agreements.
Data Security
Clinovian uses reasonable administrative, technical, and organisational safeguards designed to protect information against unauthorised access, disclosure, alteration, and destruction. No website, email system, or transmission method is completely secure, and Clinovian cannot guarantee the absolute security of information transmitted to or from the website.
International Processing
Clinovian operates and may process information from outside the United States, including from India. By using the website or contacting us, you understand that information may be processed, transferred, or stored in jurisdictions with different data protection laws, subject to applicable safeguards.
Your Rights
Depending on applicable law, you may have rights to request access, correction, deletion, restriction, objection, or withdrawal of consent regarding personal information we hold about you. Clinovian may need to verify your identity before responding to any such request. To exercise your rights, please contact us at contact@clinovian.com.
Third-Party Links
Our website may contain links to third-party services that Clinovian does not control. We are not responsible for the privacy practices, security, or content of those third-party sites and encourage you to review their privacy policies independently.
Updates to This Policy
Clinovian may update this Privacy Policy from time to time. The updated version will be posted on this page with a revised effective date. Continued use of the website following any update constitutes acceptance of the revised policy.
Contact
For questions regarding this Privacy Policy or the handling of your information, please contact Clinovian at contact@clinovian.com. We are operated from India.
Terms of Service
These Terms of Service govern your access to and use of the Clinovian website and related online materials, resources, and communications. By accessing or using the website, you agree to these Terms. The website is provided for informational and business inquiry purposes and may include educational material related to clinical denials, utilisation review, payer-facing strategy, and healthcare revenue integrity.
This website is intended primarily for healthcare organisations, physician advisors, revenue cycle professionals, specialty practices, RCM partners, and other professional users.
No Relationship Created by Site Use
Submitting an inquiry, sending an email, downloading a resource, or using the website does not by itself create a client relationship. A client relationship exists only if and when the parties enter into a separate written agreement. Clinovian reserves the right to decline any engagement without providing reasons.
No Legal Advice; No U.S. Legal Representation
Clinovian provides clinical consulting and physician advisory services. Nothing on this website constitutes legal advice, tax advice, accounting advice, medical treatment advice to patients, or U.S. legal representation. Use of this website does not create an attorney-client relationship, physician-patient relationship, or any other fiduciary relationship.
Where Clinovian incorporates regulatory or procedural arguments — such as ERISA procedural analysis or state external review frameworks — into clinical appeal documents, this is provided as part of clinical consulting services and does not constitute legal advice or legal representation of any kind.
Intake and Communications
Any information submitted through the website or intake workflow should be limited to what is necessary for an initial business inquiry unless and until Clinovian directs you to an approved secure workflow. You are responsible for ensuring that information you submit is accurate and that you have the right to provide it. Do not transmit protected health information through unsecured email or through this website.
Permitted Use
You may review, print, or save website materials for legitimate internal business evaluation. You may not use the website for unlawful, fraudulent, abusive, or unauthorised purposes, including:
- Using the website to build or develop a competing service
- Scraping, harvesting, or systematically extracting content or contact information
- Removing proprietary or copyright notices
- Misrepresenting Clinovian's services, credentials, or affiliation
- Transmitting unsolicited commercial communications
Intellectual Property
All website content — including text, structure, branding, graphics, design elements, downloadable materials, original clinical articles, and resource documents — is owned by or licensed to Clinovian unless otherwise stated. You may not copy, reproduce, republish, modify, distribute, display, or create derivative works from the content except for legitimate internal business evaluation or with prior written permission from Clinovian.
Educational materials, articles, insights, checklists, examples, calculators, and resource documents provided on the website are for general informational purposes only and should not be relied upon as a substitute for professional legal, compliance, financial, or medical advice tailored to a specific matter or organisation.
No Guarantee of Outcome
Any case examples, denial categories, strategic descriptions, calculators, estimates, or performance discussions on this website are illustrative only. Clinovian does not guarantee:
- Recovery of any specific denied amount
- Overturn of any appeal at any level
- Any specific timeline or financial result
- Suitability of services for every organisation, payer relationship, or claim type
Results in clinical denial recovery depend on case-specific facts, medical record quality, payer behaviour, applicable criteria, and many other variables outside Clinovian's control.
Third-Party Services and Website Availability
The website may reference or link to third-party tools, resources, platforms, or websites. Clinovian does not control and is not responsible for third-party content, services, policies, or availability. Clinovian may update, change, suspend, or discontinue any part of the website at any time without notice and does not guarantee that the website will always be available, uninterrupted, error-free, or secure.
Disclaimers and Limitation of Liability
To the maximum extent permitted by applicable law, the website and its content are provided on an "as is" and "as available" basis. Clinovian disclaims all warranties, express or implied, including warranties of merchantability, fitness for a particular purpose, non-infringement, accuracy, and availability.
To the maximum extent permitted by applicable law, Clinovian and its affiliates, founders, officers, employees, contractors, and advisers will not be liable for indirect, incidental, consequential, special, exemplary, or punitive damages arising out of or relating to website use, reliance on content, service interruptions, security incidents, or third-party acts or services.
Indemnification
You agree to indemnify and hold harmless Clinovian and its affiliates, founders, officers, employees, contractors, and advisers from claims, liabilities, damages, losses, and expenses arising from your misuse of the website, violation of these Terms, or violation of any applicable law or third-party rights.
Governing Terms and Updates
These Terms are also subject to the Clinovian Privacy Policy. Clinovian may update these Terms from time to time. The updated version will be posted on this page with a revised effective date. Continued use of the website following any update constitutes acceptance of the revised Terms.
Contact
For questions regarding these Terms, please contact Clinovian at contact@clinovian.com. We are operated from India.